T cell receptors for mesothelin cancer immunotherapy
Summary
The USPTO granted patent US12595290B2 to Fred Hutchinson Cancer Center covering binding proteins (T cell receptors) specific for mesothelin peptides Msln20-28 and Msln530-538, along with compositions and recombinant host cells for cancer immunotherapy. The patent protects methods for treating mesothelioma, pancreatic cancer, ovarian cancer, and lung cancer using these binding proteins.
What changed
The USPTO issued Patent No. US12595290B2 granting Fred Hutchinson Cancer Center exclusive rights to T cell receptor compositions targeting mesothelin-derived peptides for cancer immunotherapy. The patent covers 38 claims including the binding proteins, polynucleotides encoding them, and methods of treating cancers expressing Msln20-28 or Msln530-538 peptides.
For entities in the biotechnology and pharmaceutical sectors, this patent establishes IP barriers in the CAR-T and TCR immunotherapy space targeting mesothelin, a validated cancer antigen. Researchers and companies developing similar mesothelin-targeted therapies should assess freedom-to-operate implications and potential licensing opportunities with Fred Hutchinson Cancer Center.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
T cell receptors specific for mesothelin and their use in immunotherapy
Grant US12595290B2 Kind: B2 Apr 07, 2026
Assignee
FRED HUTCHINSON CANCER CENTER
Inventors
Thomas M. Schmitt, Aude G. Chapuis, Philip D. Greenberg
Abstract
Binding proteins specific for Msln20-28 or Msln530-538 peptides are provided herein. Polynucleotides encoding the binding proteins, as well as compositions and recombinant host cells comprising the binding proteins or polynucleotides are also provided. The compositions and recombinant host cells may be used to treat a subject having mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, a cancer wherein an Msln20-28 peptide is expressed on a tumor cell of the cancer, or a cancer wherein an Msln530-538 peptide is expressed on a tumor cell of the cancer.
CPC Classifications
C07K 14/7051 C07K 2319/00 A61K 40/11 A61K 40/32 A61K 40/4255 A61P 35/00 C12N 5/0636 C12N 2510/00
Filing Date
2019-11-08
Application No.
17291985
Claims
38
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.